Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5α)

Biotechnology and Bioengineering

Volumn 101, Issue 4, 2008, Pages 831-836

  Phue, Je Nie ^a   Sang, Jun Lee ^b   Trinh, Loc ^a   Shiloach, Joseph ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

High density; pDNA: E. coli B

Indexed keywords

CONCENTRATION (PROCESS); DNA; GENES; GLUCOSE; NUCLEIC ACIDS; ORGANIC ACIDS; STRAIN; VACCINES; WATER POLLUTION;

A CARBONS; CLINICAL STUDIES; E. COLI; ESCHERICHIA COLI B; FUTURE DEVELOPMENTS; GLYOXYLATE; GROWTH CONDITIONS; HIGH DENSITY; HIGH GLUCOSES; PDNA: E. COLI B; PLASMID DNA (PDNA); PLASMID DNAS; PRODUCTION STRATEGIES; PRODUCTION VALUES; PRODUCTION YIELDS; RECOMBINANT PROTEIN PRODUCTIONS; VIRAL DISEASES;

ESCHERICHIA COLI;

GLUCOSE; GLYOXYLIC ACID; PLASMID DNA; RECOMBINANT PROTEIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CARBON SOURCE; CONCENTRATION (PARAMETERS); DENSITY; ENDA GENE; ESCHERICHIA COLI; ESCHERICHIA COLI B; ESCHERICHIA COLI K; GENE DELETION; GENE MUTATION; NONHUMAN; PRODUCTIVITY; RECA GENE;

AIDS VACCINES; BACTERIAL PROTEINS; DNA, BACTERIAL; ENDODEOXYRIBONUCLEASES; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE DELETION; GLUCOSE; MEMBRANE PROTEINS; PLASMIDS; REC A RECOMBINASES; VACCINES, DNA;

ESCHERICHIA COLI; ESCHERICHIA COLI B;

EID: 55549128624     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21973     Document Type: Article

References (26)

1. Acambis. 2006. in Acambis company news (September 12, 2006) http://www. acambis.co.uk/default.asp?id=1728.
2. Bacon DJ, Sedegah M. 2007. Reduce production of RNA transcripts from individual DNA plasmids given in a multivalent DNA formula. Hum Vaccine 3:48-53.
3. Bell CE. 2005. Structure and mechanism of Escherichia coli RecA ATPase. Mol Microbiol 58:358-366.
4. Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, Schumann K, Nath B, Javadian A, Bagarazzi ML, Kim J, Weiner DB. 2000. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS 14:1515-1522.
5. Carnes AE, Hodgson CP, Williams JA. 2006. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 45:155-166.
6. Chartain M, Bentley LK, Kruewicz BA, Listner KM, Sun W, Lee CB. 2005. Process for large scale production of plasmid DNA by E. coli fermentation. PCT Int Appl WO2005/078115 A1.
7. Chen W, Graham C, Ciccarelli RB. 1997. Automated fed-batch fermentation with feed-back controls based on dissolved oxygen (DO) and pH for production of DNA vaccines. J Ind Microbiol Biotechnol 18:43-48.
8. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97:6640-6645.
9. Diogo MM, Queiroz JA, Prazeres DM. 2001. Studies on the retention of plasmid DNA and Escherichia coli nucleic acids by hydrophobic interaction chromatography. Bioseparation 10:211-220.
10. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ. the Vaccine Research Center 004 Study team. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194:1650-1660.
11. Hoffmann F, Weber J, Rinas U. 2002. Metabolic adaptation of Escherichia coli during temperature-induced recombinant protein production: 1. Readjustment of metabolic enzyme synthesis. Biotechnol Bioeng 80: 313-319.
12. Hsiao J, Ahluwalia M, Kaufman JB, Clem TR, Shiloach J. 1992. Adaptive control strategy for maintaining dissolved oxygen concentration in high density growth of recombinant E. coli. In: Pederson H, Matharasan R, Dibiaso D, editors (Ann NY Acad Sci). Biochemical engineering VII, 655: 320-333.
13. Jiao SS, William P, Berg RK, Hodgeman BA, Liu LJ, Repetto G, Wolff JA. 1992. Direct gene-transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 3:21-33.
14. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M. 1996. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 7:1971-1980.
15. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. the VRC 204 Study Team. 2006. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13:1267-1277.
16. Miller JH. 1992. A short course in bacterial genetics. A. laboratory manual and handbook for Escherichia coli and related bacteria. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory. pp 268-272.
17. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA. 1993. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. DNA Cell Biol 12:777-783.
18. NIAID. 2007. in NIH news (January 3, 2007) http://www3.niaid.nih. gov/ news/newsreleases/2007/FluDNAVax.htm.
19. O'Kennedy RD, Baldwin C, Keshavarz-Moore E. 2000. Effects of growth medium selection on plasmid DNA production and initial processing steps. J Biotechnol 76:175-183.
20. Phue J, Noronha SB, Hattacharyya R, Wolfe AJ, Shiloach J. 2005. Glucose metabolism at high density growth of E. coli B and E. coli K: Differences in metabolic pathways are responsible for efficient glucose utilization in E. coli B as determined by microoarrys and northern blot analyses. Biotechnol Bioeng 90:805-820.
21. Schoenfeld T, Mendez J, Storts DR, Portman E, Patterson B, Frederiksen J, Smith C. 1995. Effects of bacterial strains carrying the endA1 genotype on DNA quality isolated with wizard (TM) Plasmid purification systems. Promega Notes 53:12-19.
22. Sharpe M, Lynch D, Topham S, Major D, Wood J, Loudon P. 2007. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25:6392-6398.
23. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, Andrews CA, Koup RA, Bailer RT, Stein JA, Roederer M, Nabel GJ, Graham BS. the VRC 001 Team Study. 2007. Safety and immunogenicity of a gagpol Candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J. Acquir Immune Defic Syndr 44:601-605.
24. Wang ZJ, Le GW, Shi YH, Wegrzyn G. 2001. Medium design for plasmid DNA production based on stoichiometric model. Process Biochem 36:1085-1093.
25. Wittmann C, Weber J, Betiku E, Krömer J, Böhm D, Rinas U. 2007. Response of fluxome and metabolome to temperature-induced recombinant protein synthesis in Escherichia coli. J Biotechnol 132:375-384.
26. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. 1990. Direct gene-transfer into mouse muscle in vivo. Science 247: 1465-1468.